0RK9 Stock Chart & Stats
kr0.05
kr0.00(0.00%)
At close: 4:00 PM EDT
kr0.05
kr0.00(0.00%)
Day’s Range― - ―
52-Week Rangekr0.03 - kr1.52
Previous CloseN/A
Volume0.00
Average Volume (3M)6.90K
Market Cap
kr17.10M
Enterprise Valuekr122.60
Total Cash (Recent Filing)kr16.61M
Total Debt (Recent Filing)kr29.93M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding534,516,970
10 Day Avg. Volume9,644
30 Day Avg. Volume6,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageThe sharp reduction in leverage suggests recapitalization and/or debt reduction, lowering balance-sheet pressure. This provides more financial flexibility than the prior capital structure, although very limited equity still constrains resilience.
Loss ReductionA smaller annual loss indicates some improvement in cost or development-spending control. If sustained, this could extend the company’s runway, though profitability remains deeply negative and the improvement has not yet produced commercial scale.
Improving Free Cash Flow TrendThe improvement in free cash flow suggests cash consumption may be moderating relative to the prior year. That could support better resource allocation, but the absolute burn remains substantial and does not remove the need for external financing.
Bears Say
Minimal And Declining RevenueLimited and falling revenue confirms that the company lacks meaningful commercial scale and remains dependent on development-stage assets. Without product sales or recurring partner income, operating performance can remain volatile and difficult to sustain.
Persistent Cash BurnDeeply negative operating and free cash flow means ongoing research and corporate costs are not self-funded. Continued dependence on financing, licensing proceeds, or milestones creates dilution and liquidity risk if funding conditions or development outcomes weaken.
Thin Equity And Weak ProfitabilityA very small equity base combined with substantial losses leaves little balance-sheet protection against setbacks. It also limits the company’s ability to absorb trial failures, fund pipelines internally, or negotiate partnerships from a position of strength.
Alligator Bioscience AB News
0RK9 FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest share price was kr0.03 and its highest was kr1.52 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr17.10M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is Oct 22, 2026 which is in 54 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on Aug 26, 2026. The company reported -kr0.06 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 534,516,970 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of -kr0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in GB:0RK9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―